Effect of sublingual immunotherapy on clinical and laboratory autoimmunity.

IF 2.3 4区 医学 Q3 IMMUNOLOGY Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-12 DOI:10.2217/imt-2023-0231
Andrzej Bozek, Szymon Mućka, Martyna Miodonska, Anna Zlik, Magdalena Mroz-Dybowska
{"title":"Effect of sublingual immunotherapy on clinical and laboratory autoimmunity.","authors":"Andrzej Bozek, Szymon Mućka, Martyna Miodonska, Anna Zlik, Magdalena Mroz-Dybowska","doi":"10.2217/imt-2023-0231","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> There still are few data on the long-term safety of sublingual immunotherapy (SLIT). The aim of this study was to assess the appearance of autoimmune diseases in patients before and after SLIT. <b>Materials & methods:</b> New cases of autoimmune diseases were monitored. Patients in the SLIT group (n = 816) were compared with controls (n = 1096). <b>Results:</b> The new incidences of autoimmune diseases in the SLIT group were lower compared with the control group: 18 (2.2%) versus 58 (5.3%); p < 0.05. Systemic lupus erythematosus, psoriasis and Hashimoto appeared much more often in the control group. <b>Conclusion:</b> SLIT had no significant effect on the induction of autoimmune diseases.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"235-241"},"PeriodicalIF":2.3000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10844896/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/imt-2023-0231","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: There still are few data on the long-term safety of sublingual immunotherapy (SLIT). The aim of this study was to assess the appearance of autoimmune diseases in patients before and after SLIT. Materials & methods: New cases of autoimmune diseases were monitored. Patients in the SLIT group (n = 816) were compared with controls (n = 1096). Results: The new incidences of autoimmune diseases in the SLIT group were lower compared with the control group: 18 (2.2%) versus 58 (5.3%); p < 0.05. Systemic lupus erythematosus, psoriasis and Hashimoto appeared much more often in the control group. Conclusion: SLIT had no significant effect on the induction of autoimmune diseases.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
舌下免疫疗法对临床和实验室自身免疫的影响
背景:有关舌下免疫疗法(SLIT)长期安全性的数据仍然很少。本研究旨在评估舌下免疫疗法前后患者出现自身免疫性疾病的情况。材料与方法:监测自身免疫性疾病的新病例。将 SLIT 组患者(n = 816)与对照组(n = 1096)进行比较。结果与对照组相比,SLIT 组的自身免疫性疾病新发病率较低:18(2.2%)对 58(5.3%);P 结论:SLIT 对自身免疫疾病的发病率没有显著影响:SLIT对诱发自身免疫性疾病没有明显影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Immunotherapy
Immunotherapy 医学-免疫学
CiteScore
5.00
自引率
3.60%
发文量
113
审稿时长
6-12 weeks
期刊介绍: Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
期刊最新文献
Multisystem immune-related adverse events during combined ipilimumab-nivolumab with subsequent disease progression: a case report. All models are wrong, but are some useful? Toward clinically tractable prediction of immunotherapy response in cancer. Consequences of adverse events in cancer immunotherapy combinations - a comprehensive real-world analysis. Addressing social and economic disparities in triple-negative breast cancer immunotherapy: a U.S.-focused review. Evaluating inebilizumab in the treatment of generalized myasthenia gravis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1